Share on facebook Share on Twitter Share on Google Plus Share This

Heart Diseases

There are many different types of heart diseases. The most common type is coronary artery disease, or the narrowing of the coronary arteries. This important vessel carries blood to the heart.

Doctors + Care Team

Amanda Vest, MBBS, MPH

Amanda Vest, MBBS, MPH

Title(s): Associate Medical Director, Cardiac Transplantation Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-8068
Fax #: 617-636-6030

Cardiology, heart failure, heart transplantation, mechanical circulatory support

View Full Profile

Frederick  Y. Chen, MD, PhD

Frederick Y. Chen, MD, PhD

Title(s): Chief, Cardiac Surgery; Professor of Surgery, Tufts University School of Medicine
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5590
Fax #: 617-636-6410

Surgical treatment of acquired heart disease, surgical repair of valvular heart disease, minimally invasive surgery, arrhythmia surgery, heart transplantation, circulatory assist devices, hypertrophic cardiomyopathy (HCM)

View Full Profile

Joel B. Mason, MD

Joel B. Mason, MD

Title(s): Gastroenterologist; Professor, Tufts University Schools of Medicine and Friedman School of Nutritional Science and Policy; Senior Scientist and Director, Vitamins and Carcinogenesis Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
Department(s): Medicine, Clinical Nutrition, Gastroenterology
Appt. Phone: 617-636-5883
Fax #: 617-636-1480

Nutritional aspects of gastrointestinal disease, home nutritional therapy, enteral and parenteral nutrition, nutrition and cancer prevention

View Full Profile

Nicole M Orr, MD, FACC

Nicole M Orr, MD, FACC

Title(s): Cardiologist; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 781-762-0009
Fax #: 781-255-8880

Geriatric cardiology, echocardiography

View Full Profile

Research + Clinical Trials


A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure (SpanCHFIII)

This study will randomize participants with a diagnosis of congestive heart failure and at least one risk factor for hospitalization to either a tablet computer and web based disease management program or a telephone based disease management program. Both interventions are home based with heart failure education and symptom monitoring provided by nurse managers. The nurse managers are in close communication with both the participants and the participants' physicians . The components of the disease management program have been developed at Tufts Medical Center and the New England Quality Care Alliance with studies showing improved clinical outcomes, including reduced hospitalizations. The goal of this study is to transition this successful home monitoring and disease management program to a table computer and web-based implementation to both improve clinical outcomes (reducing hospitalizations and improving self-perceived health status) and improve provider-patient satisfaction. We hypothesize that the tablet computer based disease management will decrease heart failure hospitalizations.
More information about research and clinical trials


Mechanical Circulatory Support: Measures of Adjustment and Quality of Life

The purpose of this study is to develop a measurement system to assess adjustment to mechanical circulatory support (MCS) (also referred to as a ventricular assist device [VAD]) and health-related quality of life (HRQOL) in patients with advanced heart failure who receive a VAD. The investigators refer to this measurement system as Mechanical Circulatory Support: Adjustment and Quality of Life (MCS A-QOL).
More information about research and clinical trials


HeartMate PHP™ Coronary InterventionS in HIgh-Risk PatiEnts Using a Novel Percutaneous Left Ventricular Support Device (SHIELD II)

Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 60 sites in the US. Control device will be the Abiomed Impella® Recover® LP 2.5 Percutaneous Cardiac Support System.

Additionally, the study will include a nonrandomized roll-in phase at each site. Each site must first enroll and treat up to 3 patients in the nonrandomized roll-in phase before entering the randomized phase.

Assess the safety and efficacy of the HeartMate PHP in supporting patients with severe symptomatic coronary artery disease with diminished but stable cardiovascular function, who are undergoing elective or urgent high risk percutaneous coronary interventions (PCI) but are not candidates for coronary artery bypass graft (CABG) surgery.

Proposed Indications The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent,

hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.  Nonrandomized Roll-In Phase: Up to 180 patients undergoing PCI per the Inclusion/Exclusion criteria; up to 3 roll-in patients per site.

Randomized Phase: Up to 425 patients undergoing PCI per the Inclusion/Exclusion criteria.

Data will be collected at baseline, during the PCI procedure, postprocedure, discharge, and 90 days post device removal.

All patients will have a follow-up visit at 90 days post-device removal.


More information about research and clinical trials


Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure: a randomized trial  (TAVR UNLOAD)

The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.

Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis


More information about research and clinical trials


The Global cVAD Registry Protocol

The global cVAD registry collects clinical and procedural data retrospectively from hospital medical records for patients who received one or multiple Impella devices during routine clinical care. Patients who qualify for this registry include patients who received the Impella 2.5, Impella CP, or Impella 5.0 for left ventricular support as well as the Impella RP for right ventricular support during their inpatient stay. The registry is an observational, multicenter, retrospective records review. In order to best represent real-world practice, patients receiving Impella devices will be included in the registry without pre-selection. The purpose of the registry is to capture data that reflects "real world"? use of the Implella devices in clinical practice and provide insight into patients characteristics, comorbid conditions, patterns of care, quality of care and performance measurements.
More information about research and clinical trials


Entrestotm (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

The purpose of this study is to test whether EntrestoTM, a newly approved drug for heart failure that combines sacubitril and valsartan, improves symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. EntrestoTM has been studied in only a very small number of patients with advanced heart failure, like you. This study is beind done to obtain more information on the benefits and risks of EntrestoTM in patients with advanced heart failure. Both EntrestoTM and valsartan have previously been approved by the U.S. Food and Drug Administration (FDA)for people with heart failurea nd are available by prescription from a licensed medical doctor. Currently EntrestoTM is only available under the brand name EntrestoTM, there is no generic form of EntrestoTM. You do not have to take part in this study in order to receive EntrestoTM.
More information about research and clinical trials


Prospective Hemodynamic Assessment of Cardica Resynchronization Therapy Effectiveness Following Left Ventricular Assist Device Support

To understated the effects of different pacemaker settings on heart function in patients with LVADS.
More information about research and clinical trials


A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure

This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More information about research and clinical trials

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class teaching hospital shouldn’t make you feel small.  At Tufts Medical Center the patient is at the center of everything that we do.  This means we’re committed to providing the highest quality of care in a safe, friendly environment.

Learn more
The City of Boston shows the harbor and buildings

200 Years of Caring for the Community

Tufts Medical Center has been taking care of Boston and the surrounding community for more than 200 years.

Read about our enduring history